Renovia is a relatively new healthcare company that is dedicated to researching, diagnosing, and developing products to improve the lives of women that are suffering from diseases. Marc Beer co-founded Renovia in Boston back in 2016 and he has been focused on leading the company toward a brighter future ever since.
Marc has an extensive background in pharmaceuticals, biotechnology, and the healthcare industry in general and his expertise has been put on display for the healthcare community to see. After a successful Series A funding in 2016 when Renovia opened, Marc Beer added another successful funding round for Renovia last year. Marc’s company gained several new investors and managed to pool more than 40 million dollars to aid in diagnoses and medical equipment development.
According to researcher estimates, there are currently around 250 million women suffering from pelvic floor disorders globally. Pelvic floor disorder is the primary focus at Renovia, for the time being, and they recently had their first product approved by the FDA in 2018. Leva is the first of several products that Renovia is working on to be approved so it will be the first to see public use as it goes through more extensive testing.
Leva is not the first time Marc Beer has pushed to have a drug approved by the FDA. At his former company, Marc worked to develop a drug known as Juxtapid, which would treat people faced with unusually high cholesterol, which can lead to heart conditions like atherosclerosis. Unfortunately, Marc was shut down rather abruptly when his product didn’t get approved by the FDA, suggesting that the drug was mislabeled to treat heart conditions rather than high cholesterol.
This setback inspired Marc Beer to check all the bases this time around at Renovia and now he is on a path to improve women’s health around the world. With the recent approval of Leva, Renovia has gained more traction and support throughout the medical community in Boston as well. The future looks good for Leva but Marc believes they will need more time and funding to help the product truly shine as a digital health platform for all women. The medical industry has only just begun to truly delve into digital health with the latest advancements in technology and Renovia will perhaps be one of the first to make real headway with an effective and widespread medical device. Learn more: https://www.businesswire.com/news/home/20180821005199/en/Renovia-Completes-42.3-Million-Series-Financing